This study aimed to investigate the cumulative radiation dose (CRD) of patients with hepatocellular carcinoma (HCC) treated with transcatheter arterial chemoembolization (TACE). This survey was performed to examine the computed tomography (CT) and TACE radiation doses. A total of 369 cases (157 patients) underwent TACE from July 2012 to November 2018. Among them, 132 cases (66 patients) that underwent (i) TACE as the initial treatment, (ii) performed by a single physician, and (iii) whose total exposure information, was available were included in this study. Radiation doses for TACE, CT angiography during TACE, follow-up CT, and CT immediately before the first TACE were included in the survey. CRD was expressed using an effective dose, and was calculated by multiplying the dose area product (DAP) and dose length product (DLP) based on respective conversion factors.
CRD was 323.6±214.5 mSv, and CT accounted for 80% of CRD. CRD of follow-up CT was directly proportional to the survival time (r = 0.986, P < 0.001). Hence, CRD was affected by the survival time and TACE doses. Additionally, patients should undergo routine CT examination; thus, reducing the radiation dose in one examination effectively decreases CRD. In addition, some factors increased the total radiation dose in TACE; therefore, prior treatment planning may lead to dose reduction in these cases.
抄録全体を表示